Open AccessThis article is
- freely available
Coenzyme Q10 and Neurological Diseases
Department of Neuroscience, Neurological Clinic, University of Pisa, Tuscany, Italy
* Author to whom correspondence should be addressed.
Received: 29 September 2009; in revised form: 26 November 2009 / Accepted: 30 November 2009 / Published: 1 December 2009
Abstract: Coenzyme Q10 (CoQ10, or ubiquinone) is a small electron carrier of the mitochondrial respiratory chain with antioxidant properties. CoQ10 supplementation has been widely used for mitochondrial disorders. The rationale for using CoQ10 is very powerful when this compound is primary decreased because of defective synthesis. Primary CoQ10 deficiency is a treatable condition, so heightened “clinical awareness” about this diagnosis is essential. CoQ10 and its analogue, idebenone, have also been widely used in the treatment of other neurodegenerative disorders. These compounds could potentially play a therapeutic role in Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, Friedreich’s ataxia, and other conditions which have been linked to mitochondrial dysfunction. This article reviews the physiological roles of CoQ10, as well as the rationale and the role in clinical practice of CoQ10 supplementation in different neurological diseases, from primary CoQ10 deficiency to neurodegenerative disorders.
Keywords: coenzyme Q10; idebenone; mitochondria; mitochondrial diseases; neurodegeneration
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Mancuso, M.; Orsucci, D.; Calsolaro, V.; Choub, A.; Siciliano, G. Coenzyme Q10 and Neurological Diseases. Pharmaceuticals 2009, 2, 134-149.
Mancuso M, Orsucci D, Calsolaro V, Choub A, Siciliano G. Coenzyme Q10 and Neurological Diseases. Pharmaceuticals. 2009; 2(3):134-149.
Mancuso, Michelangelo; Orsucci, Daniele; Calsolaro, Valeria; Choub, Anna; Siciliano, Gabriele. 2009. "Coenzyme Q10 and Neurological Diseases." Pharmaceuticals 2, no. 3: 134-149.